Join
Live feed
·
PRReleasevia Quantisnow
AzurRx BioPharma, Inc. logo

AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications

ByQuantisnow·Wall Street's wire, on your screen.
AZRX· AzurRx BioPharma, Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AZRX (AzurRx BioPharma, Inc.) and more on Quantisnow.